Notice for zanidatamab (BeOne Medicines AUS Pty Ltd)
Active ingredients
zanidatamab
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
lyophilised powder for concentrate for solution for infusion, vial
Indication
Treatment of biliary tract carcinoma
Therapeutic area
Oncology